Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Afatinib (Primary) ; Ruxolitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Oct 2017 Updated analysis results (n=21) assessing safety and efficacy of the combination of afatinib and ruxolitinib in NSCLC patients who had progressed on EGFR-TKIs, were presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Status changed from planning to recruiting, according to results presented at the 18th World Conference on Lung Cancer. As of june 14, 2017, 21 patients were enrolled in dose-escalation cohort (DAC).
    • 11 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top